Branyon Integrative Medical Group Announces Study of Effects of UCB Stem Cells on HIVRelated Illness

Dec. 2, 2009 - PRLog -- Dr. Fredda Branyon, Founder and Director of Branyon Integrative Medical Group(BIMG), announced this weekend that the clinic will be performing an investigational study on treatment of HIV-related illnesses using umbilical cord derived stem cells.  The study will be overseen by Dr. Edgar Payan Arechiga and will be facilitated at BIMG’s partner hospital in Sonora, Mexico.  Patients will participate in a six month program that includes (but is not limited to) multiple sessions of umbilical cord blood-derived stem cell treatment, as well as several inpatient therapies and specific procedures that will monitor the patient’s progress for at least two years.  

“The protocol combines our diverse expertise in stem cell therapies with traditional modalities, and complementary treatments to ensure effective care of some of the most challenging patient diagnoses in HIV field,” Dr. Branyon said in an interview Saturday.  “This is an intensive six month program that offers the patient an effective treatment plan with no negative side effects routinely experienced during normal pharmaceutical treatment.”  Some of these patients have no hope of improvement with current therapies in use (although effective in many patients) and are desperately in need of alternate treatment plans tailored to their needs.

Transplanting pluripotent stem cells into subsets of HIV patients has the potential to reconstitute their immune system to effectively begin reversing the condition. Patients will be pre-screened for their suitability to the study using carefully selected criteria. “Leukapheresis may be combined with other FDA approved regimens, followed by stem cell therapy to rebuild the immune system”, Dr.Branyon said.  The stem cell therapy design aims to (1) control secondary infections and (2) manage HIV-related lymphomas, in selective patient groups. The study protocol builds on the extensive experience of BIMG and recent successful HIV trials performed by other groups in Germany and Russia.  The clear goals of the study will mean that the study outcomes will include definitively measurable outcomes that can be used for future larger clinical trials for FDA approval.

Branyon Integrative Medical Group offers its patients specialized treatment protocols which have, over the last ten years, been effectively used to treat chronic ad terminal immunodeficient diseases.  Dr. Fredda Branyon, NMD, the Founder and Director of Branyon Integrative Medical Group, collaborates with international experts in order to continually improve existing protocols.  Branyon Integrative Medical Group’s treatment strategy incorporates the best modalities of both medical worlds, mainstream and alternative, according to individual needs.

Branyon Integrative Medical Group acknowledges stem cell therapy is not an approved treatment option in the United States and is not FDA approved.  

BIMG will begin scheduling patients for this study on Monday, December 7, 2009.  For more information regarding the HIV-related illness study or any other treatment options offered by Branyon Integrative Medical Group, please call (866)524-4673 or email info@newhopemedicalcenter.com.